Dr. Sznol on the Use of Immunotherapy in Melanoma

In Partnership With:

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the use of immunotherapy in melanoma.

There are 2 major immunotherapeutic options in melanoma, says Sznol. Talimogene laherparepvec (T-VEC; Imlygic) could be considered a third option. However, T-VEC is rarely used in the clinic, says Sznol. The 2 most important drug classes are anti–PD-1 agents, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and anti–CTLA-4 agents, such as ipilimumab (Yervoy). Single-agent anti–PD-1 therapy can lead to long-term survival rates in the range of 40% to 45%, says Sznol. The addition of an anti–CLTA-4 agent could add another 7% to 10% to that 5-year survival rate.

Anti–PD-1 agents are commonly used alone or in combination with an anti–CTLA-4 agent in the frontline setting in patients with metastatic melanoma, concludes Sznol.

Related Videos
Beryl Manning-Geist, MD
Jung-Yun Lee, MD, PhD
Brian Mitzman, MD, FACS, FCCP
Andrew Kin, MD
Nathalie McDowell Johnson, MD, FACS
Ursula A. Matulonis, MD
Cara A. Mathews, MD
William M. Sikov, MD
Pannaga G. Malalur, MBBS
Gautam Borthakur, MD
Related Content